Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study
Latest Information Update: 15 May 2023
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms OTIS
- Sponsors Novartis
- 14 Jan 2022 Status changed from not yet recruiting to recruiting.
- 26 Oct 2021 Planned End Date changed from 2 Mar 2029 to 31 May 2032.
- 26 Oct 2021 Planned primary completion date changed from 1 Mar 2029 to 31 May 2032.